Arena Pharmaceuticals' Q1 Loss Widens 34% Despite Belviq's Sales Surge

Weight control management biopharmaceutical Arena Pharmaceuticals reports a widening loss despite a near-tripling in revenue.

May 12, 2014 at 4:48PM

Arena Pharmaceuticals (NASDAQ:ARNA), a biopharmaceutical company primarily focused on weight control management drug Belviq, this afternoon reported strong sales growth of its lead product in the first quarter, but also produced a much wider net loss than in the prior-year period.

For the quarter, Arena delivered $6.8 million in revenue, up 187% from the prior-year period as it recognized $2.9 million in Belviq net product sales (representing its 31.5% share of partner Eisai Pharmaceuticals' reported $8.4 million in total sales) compared to $0 in Q1 2013, and saw its collaborative revenue with Eisai more than double to $3.3 million from $1.5 million. As noted in the report, Belviq prescriptions written surged 31% to 77,000 in Q1 with more than 60% of people in the U.S. now estimated to be insurance eligible in some way to receive Belviq.

However, costs associated with Belviq and the remainder of Arena's pipeline also rose, sending research and development expenses up to $21 million from $14 million in the year-ago quarter, and pushing total operating expenses higher by 30% to $30.4 million.

Net loss for the quarter widened by 34% to $25.3 million, or $0.12 per share, from $18.9 million, or $0.09 per share in the year-ago quarter. By comparison, Wall Street was anticipating a slightly narrower loss of just $0.10 per share.

Lastly, Arena announced that it ended the quarter with $256.5 million in cash, cash equivalents, and short-term investments, up from the $221.9 million reported in the sequential fourth quarter. 

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers